Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific immunotherapies for the treatment of multiple sclerosis. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders.Find a broker to begin trading OPXA now
|Company Name||Opexa Therapeutics|
|Avg. Daily Vol. (3m)||598,341|
|As of Dec. 8, 2016|